107 Results for "

PD-L1 Protein

" in MedChemExpress (MCE) Product Catalog:
Products (107)

107 Results for "PD-L1 Protein" in MCE Product Catalog:

32
32 Publications Verification
Cat. No.: HY-19991
CAS No.: 1675201-83-8
Synonyms: PD-1/PD-L1 inhibitor 1
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

BMS-1 is an inhibitor of the PD-1/PD-L1 protein/protein interaction (IC50 between 6 and 100 nM) .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-100022
CAS No.: 1849590-01-7
Purity:  99.92%
Synonyms: eFT508
Target:  

MNK PD-1/PD-L1

Research Areas:  

Cancer

Tomivosertib (eFT508) is a potent, highly selective, and orally active MNK1 and MNK2 inhibitor, with IC50s of 1-2 nM against both isoforms. Tomivosertib (eFT508) treatment leads to a dose-dependent reduction in eIF4E phosphorylation at serine 209 (IC50=2-16 nM) in tumor cell lines . Tomivosertib (eFT508) also dramatically downregulates PD-L1 protein abundance .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P73361
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD274; B7 Homolog 1; Prev. PDCD1LG1; B7-H; PD-L1; PDCD1 Ligand 1; B7H1; PDCD1L1; PDL1; HPD-L1; Programmed Cell Death 1 Ligand 1; Programmed Death Ligand 1; CD274 Antigen; ADMIO5; CD274 Molecule; B7-H1
Species:  
Source:  
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P9919A
CAS No.: 1428935-60-7
Synonyms: MEDI 4736 (anti-PD-L1)

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N0242
CAS No.: 28808-62-0
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1 .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-101093
CAS No.: 1673534-76-3
Purity:  99.39%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P70632
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD274; B7 Homolog 1; Prev. PDCD1LG1; B7-H; PD-L1; PDCD1 Ligand 1; B7H1; PDCD1L1; PDL1; HPD-L1; Programmed Cell Death 1 Ligand 1; Programmed Death Ligand 1; CD274 Antigen; ADMIO5; CD274 Molecule; B7-H1
Species:  
Source:  
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-144088
CAS No.: 2380300-79-6
Purity:  98.86%
Synonyms: HPK1-IN-22
Target:  

MAP4K

Research Areas:  

Inflammation/Immunology Cancer

ZYF0033 is an orally active inhibitor of the hematopoietic progenitor cell kinase HPK1 with an IC50 of less than 10 nM based on the phosphorylation inhibition of MBP protein. ZYF0033 promotes anti-cancer immune responses and reduces phosphorylation of SLP76 (serine 376). ZYF0033 inhibits tumor growth in the 4T-1 syngeneic mouse model and leads to increased intratumoral infiltration of DCs, NK cells, and CD107a +CD8 + T cells, but not T cells, PD-1 +CD8 + T cells, TIM-3 +CD8 + Infiltration of T cells and LAG3 +CD8 + T cells was reduced .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-139781
CAS No.: 2767424-13-3
Purity:  98.01%
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

PD-L1-IN-1 (Compound 10) is a potent PD-L1 inhibitor with an IC50 of 115 nM. PD-L1-IN-1 strongly binds with the PD-L1 protein and challenged it in a co-culture of PD-L1 expressing cancer cells and peripheral blood mononuclear cells enhanced antitumor immune activity of the latter. PD-L1-IN-1 significantly exhibits low cytotoxicity in healthy cells .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P7397
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD274; B7 Homolog 1; Prev. PDCD1LG1; B7-H; PD-L1; PDCD1 Ligand 1; B7H1; PDCD1L1; PDL1; HPD-L1; Programmed Cell Death 1 Ligand 1; Programmed Death Ligand 1; CD274 Antigen; ADMIO5; CD274 Molecule; B7-H1
Species:  
Source:  
CHO
loading...
    loading...
Cat. No.: HY-P99115
CAS No.: 2102192-68-5
Synonyms: ASC 22; KN 035

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors .
loading...
    loading...
Cat. No.: HY-111485
CAS No.: 1820889-23-3
Purity:  98.29%
Synonyms: INCB-057643
Research Areas:  

Cancer

Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer .
loading...
    loading...
Cat. No.: HY-163757
CAS No.: 3052114-77-6
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PROTAC PD-L1 degrader-1 is a CRBN-based PD-L1-PROTAC degrader with a notable PD-L1 protein degradation capability. PROTAC PD-L1 degrader-1 shows potent PD-L1 degradation in 4T1 cells with a DC50 of 0.609 μM. PROTAC PD-L1 degrader-1 can be used for the study of breast cancer .
loading...
    loading...
Cat. No.: HY-P99944
CAS No.: 2891860-17-4
Synonyms: Retlirafusp alfa

Research Areas:  

Cancer

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research .
loading...
    loading...
Cat. No.: HY-178193
Research Areas:  

Cancer

Chem-0199 is an Adipocyte Enhancer-Binding Protein 1 (AEBP1) inhibitor. Chem-0199 can disrupt the interaction between AEBP1 and CKAP4, thereby enhances antitumor immunity. Chem-0199 can inhibit Akt phosphorylation (p-Akt) and downregulates PD-L1 expression. Chem-0199 can be used for the research of cancer, such as colon cancer .
loading...
    loading...
Cat. No.: HY-138407
CAS No.: 2374856-75-2
Purity:  98.14%
Synonyms: GS-4224; PD-1/PD-L1-IN 7
Target:  

PD-1/PD-L1 HBV

Research Areas:  

Infection Cancer

Evixapodlin (GS-4224) is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. Evixapodlin has anticancer and antiviral functions .
loading...
    loading...
Cat. No.: HY-P99618
CAS No.: 2377419-89-9
Synonyms: IBI-315; BH2950

Target:  

EGFR PD-1/PD-L1

Research Areas:  

Cancer

Fidasimtamab is a bispecific antibody targeting human epidermal growth factor receptor 2 (Her2) and programmed death protein 1 (PD-1), with a Ka of 3.55e-10 M for human Her2 and a Ka of 1.17e-9 M for human PD-1. Fidasimtamab cross-links Her2-positive tumor cells with PD-1-positive T cells to form immune synapses, blocks PD-1-ligand interactions, preserves antibody-dependent cellular cytotoxicity, induces gasdermin B (GSDMB)-mediated pyroptosis, and activates T cells. Fidasimtamab is applicable to relevant research on Her2-positive gastric cancer .
loading...
    loading...
Cat. No.: HY-131183
CAS No.: 2447066-37-5
Purity:  99.52%
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
loading...
    loading...
Cat. No.: HY-N14001
CAS No.: 2227550-73-2
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors .
loading...
    loading...
Cat. No.: HY-168530
CAS No.: 3122200-59-0
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PDL1 degrader-1 (compound PMT-O9-1A) is a potent PD-L1 degrader. PDL1 degrader-1 decreases the protein expression of PD-L1. PDL1 degrader-1 shows cytotoxicity. PDL1 degrader-1 shows anticancer activity .
loading...
    loading...